Annexin’s business model is based on maintaining and strengthening its leading position within the Annexin A5 field for the treatment of cardiovascular diseases while minimizing development risks and optimizing the value of the ANXV program prior to a partnership, licensing or sale.
In summary, Annexin’s strategy consists of the following elements:
Focus on cardiovascular diseases where there is a high unmet medical need
Development of ANXV for the treatment of retinal vein occlusion (RVO), under own management
The goal is to carry out clinical efficacy studies (at least through phase II) completely on our own, to increase the possibility that an agreement of partnership, licensing or sale can be reached with favourable terms for the Company. In an overall assessment, the time frames and costs of taking the drug candidate ANXV to first market approval in the treatment of RVO are expected to be less than for a traditional drug project.
Optimize the value and potential of ANXV through a focus on partnership
The Company intends to conclude phase II studies on its own in the prioritized indication RVO, in order to increase the possibility that an agreement of partnership, licensing or sale can be reached with favorable terms for the Company. In parallel with its own development of ANXV in RVO, the Company intends to seek one or more partners for cooperation, licensing or sale of ANXV in other cardiovascular diseases. The Company does not give any forecasts for when a possible partnership is expected to be entered into, but is continuously evaluating different opportunities.